Promising ROd-cone DYstrophy Gene therapY

计划入组 33 人 · 首次发布于 2023 年 3 月 1 日

Study of New Mutations in Cone Disorders

计划入组 7 人 · 首次发布于 2020 年 12 月 8 日

Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy

计划入组 10 人 · 首次发布于 2016 年 2 月 2 日

FOV 2501

KCNV2 CRISPR/Cas9 gene therapy (AAV, cone dystrophy)

Genetic Muscular Dystrophy program

The Moses H. Cone Memorial Hospital Operating Corporation

United States

Dyne Therapeutics

United States

Sarepta Therapeutics, Inc.

United States

FDA Grants Fast Track Status to BlueRock's Novel Cell Therapy for Inherited Retinal Diseases

Ocugen's OCU410ST Receives Orphan Drug Designation from EMA for ABCA4 Retinopathies

Ocugen's OCU410ST Receives EMA Orphan Drug Designation for ABCA4-Associated Retinopathies